Freshfields advises on the sale of HELM Pharmaceuticals to Noucor

Global law firm Freshfields has advised HELM AG on the sale of its finished dosage form business, HELM Pharmaceuticals, to Noucor.

HELM Pharmaceuticals has been developing finished dosage form products for 30 years, giving customers access to a broad portfolio of molecules across various therapeutic areas and dosage forms, as well as to a pipeline of ongoing development projects, with significant commercial activities in Europe and the US. The HELM group is a global, family-owned chemical distribution and marketing company headquartered in Hamburg, Germany, with operations in more than 30 countries; its focus areas are chemicals, crop solutions and specialty & advanced materials.

Noucor is an international healthcare group, backed by MCH Private Equity and a group of local family offices, dedicated to the development, manufacturing and commercialisation of pharmaceutical products. Headquartered in Barcelona, the company operates across multiple international markets.

The Freshfields team was led by Partner Steffen Kleefass together with Principal Associates Stephan Reemts and Viviane Cismak, as well as Associate Benedikt Grosch (all Corporate/M&A, Frankfurt).

The Freshfields team also included:

Partners: Uwe Salaschek (Antitrust, Berlin), Sebastian Röger (Tax, Frankfurt) Elisabeth Wulf (Commercial/IP, Hamburg), Frank Schaer (Employment Law, Frankfurt)

Principal Associates: Hendrik Menzel (Tax, Frankfurt), Maximilian Zellerhoff (Commercial/IP, Hamburg), Sarah Kutsche (Real Estate, Düsseldorf), Johanna Hirth, Fabian Zöpfchen (both Employment Law, Frankfurt)

Associates: Christoph Scholtke (Corporate/M&A, Frankfurt), Matthias Wahls, Christoph Sickinger (both Antitrust, Berlin), Zahar Qasim (Commercial/IP, Hamburg), Felix Krippner (Real Estate, Frankfurt)